Horizon 2020 SME
News
Dec 2017

Dutch Life Science VCs Swanbridge and Health Innovtions investment helps FABPulous to market

Rotterdam, October 10th, 2017 – Dutch medical start-up FABPulous B.V. welcomed a new round of investment on Tuesday led by Dutch Life Science Venture fund Swanbridge Capital that

Read More

 

 

Dec 2017

FABPulous founder Jan Glatz Nominated for European Inventor 2018

MAASTRICHT, Oct 16, 2017 – The EASME at the European Commission nominated FABPulous BV’s founder Jan Glatz and Ger Biesbrouck of Medavinci Development, Amsterdam on Monday for the

Read More

 

 

Aug 2017

FABPulous Wins New EU Patents for Unique Integrated Assay Concept

Maastricht, Netherlands, May 3, 2017 – Dutch point of care diagnostics solution company FABPulous BV won new patents across the European Union on Wednesday for the unique Integrated

Read More

 

 

Aug 2015

Cracking the chest pain problem

FABPulous develops and markets pioneering solutions for better diagnostics in primary care and emergency medicine More than six out of 10 people referred for observation when complaining of

Read More

 

 

Jul 2015

FABPulous wins €1.6m EU grant for clinical trials of 5 minute heart attack test

The European Union awarded FABPulous BV a €1.6 million Phase 2 grant to fund two clinical trials in the UK and Belgium/Netherlands and automate the manufacture of its

Read More

 

 

Jun 2015

FABPulous BV Announces evolved Executive Management Team

Following successful completion of the €2.2m Series B funding round, FABPulous BV reorganises roles within an enlarged management team to meet the challenges of evolution from R&D start

Read More

 

 

Jun 2015

Press Release – Successful Closure Series B Funding

FABPulous BV closes Series B Funding; Begins commercial activities with rapid 5-minute point-of-care IVD for myocardial infarction based on H-FABP February 4th 2015; Maastricht – Today FABPulous B.V.

Read More

 

 

Apr 2015

FABPulous CEO Interview at Horizon 2020 launch in Brussels

FABPulous was delighted to be notified in December 2014 that it would be awarded an exceptional 100% contribution grant for €1.63m to fund clinical trials for use of

Read More